Elisabete Weiderpass1, Jerome Antoine2, Freddie I Bray3, Jin-Kyoung Oh4, Marc Arbyn2. 1. Cancer Registry of Norway, Oslo, Norway; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Department of Community Medicine, UiT The Arctic University of Norway, Tromsø, Norway; Department of Genetic Epidemiology, Folkhälsan Research Center, Helsinki, Finland. Electronic address: elisabete.weiderpass@ki.se. 2. Unit of Cancer Epidemiology, Scientific Institute of Public Health, Brussels, Belgium. 3. International Agency for Research on Cancer, Lyon, France. 4. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Risk Appraisal and Prevention Branch, National Cancer Center, Goyang, Republic of Korea.
Abstract
OBJECTIVES: The burden of corpus uteri cancer varies in the European Union (EU). We analysed trends in corpus uteri cancer mortality in 26 EU member states from 1970 onward. METHODS: Population numbers and number of uterine cancer deaths were extracted from the World Health Organisation mortality database. Corpus uteri cancer mortality rates were corrected for certification problems using different reallocation rules for deaths registered as uterine cancer not otherwise specified, or using mixed disease codes. Join point regression was used to study the annual percentage change of age-standardised corpus uteri cancer mortality rates. Changes in corpus uteri cancer mortality rates by calendar period and standardised cohort mortality ratios were also estimated. RESULTS: In 2008, 12,903 women died from corpus uteri cancer in the EU. Corrected age-standardised corpus uteri cancer mortality rates have decreased significantly over the past decades in most member states, with exception of Malta and Bulgaria, where rates increased; Greece, where rates remained low but stable; and Sweden, where rates have been stable since 1970. Original member states showed a steeper decrease than newer member states. The standardised cohort mortality ratios indicated that corpus uteri cancer mortality does not decrease further, nor does it increase, among women born after 1940, although these birth cohorts may still be too young for corpus uteri cancer incidence to be fully evaluated. CONCLUSION: Our corrected corpus uteri cancer mortality rates showed a decrease in most EU member states among women born before 1940.
OBJECTIVES: The burden of corpus uteri cancer varies in the European Union (EU). We analysed trends in corpus uteri cancer mortality in 26 EU member states from 1970 onward. METHODS: Population numbers and number of uterine cancer deaths were extracted from the World Health Organisation mortality database. Corpus uteri cancer mortality rates were corrected for certification problems using different reallocation rules for deaths registered as uterine cancer not otherwise specified, or using mixed disease codes. Join point regression was used to study the annual percentage change of age-standardised corpus uteri cancer mortality rates. Changes in corpus uteri cancer mortality rates by calendar period and standardised cohort mortality ratios were also estimated. RESULTS: In 2008, 12,903 women died from corpus uteri cancer in the EU. Corrected age-standardised corpus uteri cancer mortality rates have decreased significantly over the past decades in most member states, with exception of Malta and Bulgaria, where rates increased; Greece, where rates remained low but stable; and Sweden, where rates have been stable since 1970. Original member states showed a steeper decrease than newer member states. The standardised cohort mortality ratios indicated that corpus uteri cancer mortality does not decrease further, nor does it increase, among women born after 1940, although these birth cohorts may still be too young for corpus uteri cancer incidence to be fully evaluated. CONCLUSION: Our corrected corpus uteri cancer mortality rates showed a decrease in most EU member states among women born before 1940.
Authors: Megan A Clarke; Beverly J Long; Arena Del Mar Morillo; Marc Arbyn; Jamie N Bakkum-Gamez; Nicolas Wentzensen Journal: JAMA Intern Med Date: 2018-09-01 Impact factor: 21.873